Psychosocial impact of testing human papillomavirus positive in Australia's human papillomavirus-based cervical screening program: A cross-sectional survey

Verity Chadwick1 | Kirsty F. Bennett2 | Kirsten J. McCaffery3 | Julia M. L. Brotherton4,5 | Rachael H. Dodd3

1 Royal North Shore Hospital, St Leonards, New South Wales, Australia
2 Department of Behavioural Science and Health, Cancer Communication and Screening Group, University College London, London, UK
3 Faculty of Medicine and Health, School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
4 VCS Population Health, VCS Foundation, Carlton South, Victoria, Australia
5 Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia

Abstract

Objective: To examine the impact of self-reported human papillomavirus (HPV) test result (HPV negative, HPV positive, HPV result unknown) on a range of psychosocial outcomes.

Methods: Women and other people with a cervix in Australia aged 25–74 years who reported having participated in cervical screening since December 2017 were recruited through Facebook and Instagram to complete an online survey. The primary outcome measures were anxiety, emotional distress, and general distress.

Results: Nine hundred fifteen participants completed the online survey; 73.2% reported testing HPV negative (‘HPV−’), 15% reported testing HPV positive (‘HPV+’) and 11.8% reported that they did not know/remember their test result (‘HPV unknown’). Compared to participants testing HPV−, participants testing HPV+ had higher mean anxiety (41.67 vs. 37.08, p < 0.001) and emotional distress scores (11.88 vs. 7.71, p < 0.001). Concern about test result (34.3% vs. 1.3%, p < 0.001), perceived risk compared to average women (55.4% vs. 14.1%, p < 0.001), and cancer worry (27.8% vs. 5.9%, p < 0.001) were also greater among HPV+ participants than participants testing HPV−. Participants testing HPV+ felt less reassured about their screening result than participants testing HPV− (16% vs. 75.1%, p < 0.001). Participants testing HPV+ had greater knowledge of HPV (11.96 vs. 10.36 out of 16, p < 0.001) and HPV testing (3.94 vs 3.28 out of 5, p < 0.001) than participants who reported testing HPV−.

Conclusions: Elevated levels of anxiety and emotional distress were found in those testing HPV+ compared with those testing HPV−. Future research should examine
what strategies should be used to deliver test results and what additional information is provided, in order to alleviate anxiety among individuals testing HPV+.

**KEYWORDS**
anxiety, cancer, early detection of cancer, oncology, papillomavirus infections, psychological distress

**Key points**

- Anxiety and emotional distress are significantly greater in individuals who report testing human papillomavirus positive (HPV+)
- Knowledge of human papillomavirus (HPV) is high in individuals who report testing HPV+, but there are still some significant knowledge gaps
- Future research is needed to examine how individuals should best receive HPV test results, and what resources should be provided

1 | **INTRODUCTION**

Cervical cancer is the fourth most commonly diagnosed cancer worldwide, but in Australia cervical cancer prevalence is at an all-time low. This is largely due to high uptake of cervical screening and widespread uptake of the human papillomavirus (HPV) vaccine. The HPV-based screening program, introduced in December 2017, is thought to be more effective at reducing incidence and mortality due to cervical cancer than the previous program using cervical cytology (Pap) testing. HPV testing has higher sensitivity for the detection of pre-cancerous lesions, facilitating longer screening intervals.

Given that HPV is transmitted sexually, prior research has shown shame and stigma to be associated with the disclosure of positive results to partner, family and friends; judgment from others; and the belief that negative connotations (such as sexual promiscuity) are associated with HPV. We conducted a survey in 2017 to measure anxiety and distress levels shortly following the implementation of HPV-based screening, and found participants (women and other people with a cervix) who received HPV+ results, had significantly higher levels of anxiety and distress. These effects are similar to responses observed in the broader sexually transmitted infection (STI) literature. Fears of malignancy, partner infidelity, potential transmission, pain caused by colposcopy and treatment, and of future infertility have commonly been reported post communication of a HPV+ result. These psychosocial stressors may have become more widespread now that HPV testing is a routine part of cervical screening, as around 8% of women and other people with a cervix test HPV+ in Australia’s program. Although only a small proportion of these individuals may experience anxiety or distress due to a HPV+ result, given the large numbers who attend for cervical screening each year, this would still equate to a large number of individuals experiencing a heightened emotional response. Given the potential proportion of individuals testing HPV+ since implementation of the renewed cervical screening program, this study aimed to examine the psychosocial impact of primary HPV screening among Australians a further year into the renewal of the cervical screening program, in a sample recruited via social media.

2 | **MATERIALS AND METHODS**

2.1 | **Sample**

Eligible participants were individuals residing in Australia aged 25–74 who had undergone cervical screening since 1 December 2017 under the renewed National Cervical Screening Program (NCSP). Participants were excluded if they had no capacity to consent, had a previous diagnosis of cervical cancer or had undergone a hysterectomy.

2.2 | **Procedure**

Participants were recruited using targeted paid advertising on Facebook and Instagram between 13 and 23 March 2020, to ‘complete a short survey about cervical screening’. Participants could enter a prize draw to win one of twenty $AUD20 vouchers. A web-link directed participants to read the participant information statement, provide consent to participate (via a tick-box), and complete a cross-sectional survey eliciting sociodemographic, clinical, and other background information.

2.3 | **Measures**

Participants completed sociodemographic and clinical information adapted from previous studies of cervical screening attitudes in women/patients. Primary outcomes were anxiety, measured using the State-Trait Anxiety Inventory (STAI-6), and emotional and general distress, using the Cervical Screening Questionnaire and General Health Questionnaire (GHQ-12) respectively. Secondary
outcomes included psychosexual distress (modified versions of the Psychosocial Effects of Abnormal Pap Smears Questionnaire short-form [PEAPS-Q-5]), cancer worry, understanding of HPV results, perceived risk of developing cervical cancer, concern regarding screening results, future screening intention and a validated measure of knowledge of HPV (16 items) and HPV testing (5 items).  

2.3.1 Perceived risk of cervical cancer

Perceived lifetime risk was assessed using ‘What are your chances of developing cervical cancer in your lifetime?’ (no/low/medium/high chance; recoded as ‘no/low chance’ and ‘medium/high chance’). Perceived risk compared to another woman with similar characteristics was assessed using ‘What is your lifetime chance of getting cervical cancer compared to a woman of your age and race without any known risk factors?’ (much below/ below average; slightly below average/same average risk recoded as ‘average/ below average’: slightly above/much above average recoded as ‘above average’).

2.3.2 Cancer worry

Worry about developing cervical cancer was assessed using ‘How worried are you of getting cervical cancer in your lifetime?’ (not at all/ a bit worried recoded as ‘lower worry’; quite/very worried recoded as ‘higher worry’).

2.3.3 Concern about test results

Concern about test results was assessed using ‘How concerned do you feel about your recent cervical screening result?’ (not at all/ slightly/somewhat concerned recoded as ‘lower concern’; moderately/very concerned recoded as ‘higher concern’).

2.3.4 Reassurance about test results

Reassurance about test results was assessed using ‘How reassured do you feel about your recent cervical screening result?’ (not at all/ slightly reassured recoded as ‘lower reassurance’; somewhat/ moderately/very reassured recoded as ‘higher reassurance’).

2.3.5 Knowledge of HPV and HPV testing

Knowledge of HPV was assessed using ‘Before today had you ever heard of human papillomavirus (HPV)?’ (yes/no). Those responding ‘yes’ answered statements assessing knowledge of HPV (16 statements) and HPV testing (5 statements) as ‘true’, ‘false’ or ‘don’t know’.

2.4 Sample size

With a minimum sample of 1000 participants, and assuming approximately 7.5% of the sample is HPV+ and equal standard deviations of 14.6 on the STAI in both HPV+ and HPV− groups (based on previous work), a 95% confidence interval no wider than ±3.44 units (0.24 standard deviations) around the mean would be achievable.

2.5 Analysis

Analyses were carried out using SPSS v22. Differences in the demographic characteristics between the three result groups (HPV+, HPV−, HPV unknown) were described descriptively. Variation in anxiety, general distress, emotional distress, knowledge of HPV and HPV testing across the three result groups were explored using ANCOVA. In the anxiety, general distress and emotional distress analyses, we adjusted for age, education, country of birth, relationship status, and cervical screening pre-December 2017. In the knowledge of HPV and HPV testing analyses, we additionally adjusted for HPV vaccine receipt. After establishing main effects, post-hoc tests using a Bonferroni adjustment were used to explore differences between groups.

Multivariate logistic regression models explored whether perceived risk of cervical cancer, cancer worry, and concern and reassurance about test results were associated with HPV test result outcome (adjusting for age, education, country of birth, relationship status and cervical screening pre-December 2017). Odds ratios, indicating increased or decreased odds for the outcome for each group compared to the HPV− group, with 95% confidence intervals and p values, were calculated.

Data collection was stopped prior to the minimum sample being achieved due to the start of the COVID pandemic, to minimize general anxiety and distress measures being confounded by the pandemic.

3 RESULTS

Of the 100,712 impressions (number of advertisement views; views may not be unique each time), 2302 clicked through to the survey. From this, 1312 began the survey and 922 unique responses were achieved due to the start of the COVID pandemic, to minimize general anxiety and distress measures being confounded by the pandemic.
|                          | HPV+ (n = 137) | HPV− (n = 670) | HPV unknown (n = 108) | Total (n = 915) |
|--------------------------|----------------|----------------|----------------------|-----------------|
|                          | n (%)          | n (%)          | n (%)                | n (%)           |
| **Age**                  |                |                |                      |                 |
| 25–39                    | 101 (73.7)     | 412 (61.5)     | 61 (56.5)            | 574 (62.7)      |
| 40–54                    | 24 (17.5)      | 157 (23.4)     | 35 (32.4)            | 216 (23.6)      |
| 55–69                    | 11 (8.0)       | 97 (14.5)      | 12 (11.1)            | 120 (13.1)      |
| 70–74                    | 1 (0.7)        | 4 (0.6)        | 0 (0)                | 5 (0.5)         |
| **Level of education**   |                |                |                      |                 |
| High                     | 124 (90.5)     | 610 (91.0)     | 98 (90.7)            | 832 (90.9)      |
| Medium                   | 7 (5.1)        | 39 (5.8)       | 5 (4.6)              | 51 (5.6)        |
| Low                      | 6 (4.4)        | 21 (3.1)       | 5 (4.6)              | 32 (3.5)        |
| **Employment**           |                |                |                      |                 |
| Full time                | 84 (61.3)      | 297 (44.3)     | 47 (43.5)            | 428 (46.8)      |
| Part time                | 33 (24.1)      | 221 (33.0)     | 40 (37.0)            | 294 (32.1)      |
| Other                    | 20 (14.6)      | 152 (22.7)     | 21 (19.4)            | 193 (21.1)      |
| **Relationship status**  |                |                |                      |                 |
| Single/dating            | 44 (32.1)      | 114 (17.0)     | 16 (14.8)            | 174 (19.0)      |
| Married/living with partner | 70 (51.1)  | 481 (71.8)     | 79 (73.1)            | 630 (68.9)      |
| Partnered/not living with partner | 18 (13.1) | 36 (5.4)       | 4 (3.7)              | 58 (6.3)        |
| Other                    | 5 (3.6)        | 39 (5.8)       | 9 (8.3)              | 53 (5.8)        |
| **Born in Australia**    |                |                |                      |                 |
| Yes                      | 116 (84.7)     | 562 (83.9)     | 94 (87.0)            | 772 (84.4)      |
| Aboriginal or Torres Strait Islander | - | 9 (1.6) | 2 (2.1) | 11 (1.4) |
| **Non-English-speaking background** | - | 14 (2.1) | - | 14 (1.5) |
| **Received HPV vaccine** |                |                |                      |                 |
| Yes                      | 79 (57.7)      | 333 (49.7)     | 47 (43.5)            | 459 (50.2)      |
| No                       | 56 (40.9)      | 317 (47.3)     | 55 (50.9)            | 428 (46.8)      |
| Don't know               | 2 (1.5)        | 20 (3.0)       | 6 (5.6)              | 28 (3.1)        |
| **Doses of HPV vaccine received (n = 460)** | | | | |
| 1                        | 2 (2.5)        | 9 (2.7)        | 2 (4.3)              | 13 (2.8)        |
| 2                        | 9 (11.4)       | 45 (13.5)      | 3 (6.4)              | 57 (12.4)       |
| 3                        | 46 (58.2)      | 225 (67.6)     | 31 (66.0)            | 302 (65.8)      |
| Don't know               | 22 (27.8)      | 54 (16.2)      | 11 (23.4)            | 87 (19.0)       |
| **Pap smear prior to Dec 2017** | | | | |
| Yes                      | 125 (91.2)     | 611 (91.2)     | 99 (91.7)            | 835 (91.3)      |
| No/don't know            | 12 (8.8)       | 59 (8.8)       | 9 (8.3)              | 80 (8.7)        |
| **Frequency of Pap smears** | | | | |
| More frequently than recommended <2 years | 36 (28.8) | 83 (13.6) | 14 (14.1) | 133 (15.9) |
| Regular – every 2 years  | 63 (50.4)      | 328 (53.7)     | 39 (39.4)            | 430 (51.5)      |
| Less frequently than recommended >2 years | 22 (17.6) | 160 (26.1) | 39 (39.4) | 221 (26.5) |
| Only one                 | 4 (3.2)        | 40 (6.5)       | 7 (7.1)              | 51 (6.1)        | (Continues)
(46.8%). The majority of participants were born in Australia (84.4%), with 1.4% identifying as Aboriginal or Torres Strait Islander. Around half reported having received the HPV vaccine (50.2%). Most participants (91.3%) had received a Pap smear prior to December 2017 and around two-thirds of women (67%) had been screened recently, in 2019 or 2020, with 51.5% reporting regular cervical screening (every 2 years). Most participants reported testing HPV+ at their most recent cervical screening test (73.2%) with 15% testing HPV+ and 11.8% reporting that they did not know/could not remember their screening result.

### 3.1 General anxiety and distress

Mean scores for general anxiety, general distress, and emotional distress by HPV status are presented in Table 2. Anxiety differed significantly across the three HPV result groups ($F[2,899] = 5.97$, $p = 0.003$) and was highest among the HPV+ group ($\bar{X} = 41.67$, SE = 4.05) and lowest among the HPV− ($\bar{X} = 37.08$, SE = 3.88) and HPV unknown groups ($\bar{X} = 37.79$, SE = 4.04). Post-hoc tests revealed that participants in the HPV+ group had significantly higher anxiety scores than participants in the HPV− group ($p = 0.002$). There were no differences between the HPV+ and HPV unknown group ($p = 0.098$) or the HPV− and HPV unknown groups ($p = 1.00$).

General distress, measured by the GHQ-12, did not differ across the three HPV result groups ($F[2,899] = 0.75$, $p = 0.475$). Post-hoc tests also revealed no significant differences between the HPV+ and HPV− groups ($p = 0.691$), HPV+ and HPV unknown groups ($p = 1.00$) or the HPV− and HPV unknown groups ($p = 1.00$).

### 3.2 Cervical screening specific emotional distress

Emotional distress, measured by the CSQ, was significantly different across the three HPV result groups ($F[2,899] = 92.70$, $p < 0.001$) and was highest among the HPV+ group ($\bar{X} = 11.88$, SE = 0.94) and lowest among the HPV− ($\bar{X} = 7.71$, SE = 0.90) and HPV unknown groups ($\bar{X} = 8.01$, SE = 0.94). Post-hoc tests revealed that participants who reported testing HPV+ had significantly higher emotional distress scores than participants who reported testing HPV− and HPV unknown (both $p < 0.001$). There was no difference between the HPV− and HPV unknown groups ($p = 1.00$).

### 3.3 Perceived risk

Compared to participants who reported testing HPV−, participants who reported testing HPV+ were significantly more likely to perceive themselves to be at above average risk of developing cervical cancer in their lifetime (56.9% vs. 20.9%, OR = 4.69, 95% CI: 3.14–6.99, $p < 0.001$; Table 3) and of developing cervical cancer compared to another woman with similar characteristics (55.4% vs. 14.1% OR = 7.3, 95% CI: 4.8–11.1) $p < 0.001$). Participants who did not know their HPV status were also more likely to perceive themselves to be at above average risk of developing cervical cancer compared with those testing HPV− (30.6% vs. 20.9%, OR = 1.63, 95% CI: 1.03–2.57, $p = 0.037$).

### 3.4 Cancer worry

Compared to participants who reported testing HPV−, participants who reported testing HPV+ had increased odds of reporting high worry about developing cervical cancer (27.8% vs. 5.9%, OR = 5.81 95% CI: 3.47–9.73) $p < 0.001$). There was no difference between the HPV− and HPV unknown group ($p = 0.688$).

### 3.5 Concern and reassurance about test results

Compared to participants who reported testing HPV−, participants who reported testing HPV+ had increased odds of reporting high concern about their test results (34.3% vs. 1.3%, OR = 38.9, 95% CI: 17.77–85.15, $p < 0.001$). There was no difference between the HPV− and HPV unknown group ($p = 0.117$). Participants who reported testing HPV+ had lower odds of reporting reassurance about their test results (16% vs. 75.1%, OR = 0.13, 95% CI: 0.09–0.20, $p < 0.001$), as did participants who did not know their HPV status (41.7% vs. 75.1%, OR = 0.26, 95% CI: 0.17–0.42, $p < 0.001$).
### TABLE 2 Adjusted mean scores for emotional- and knowledge-related outcomes by HPV status

| Possible range of scores | Observed range of scores | Mean scores by HPV status (SE) | Mean scores by HPV status (SE) | HPV+ vs. HPV− | p value for pairwise comparisons |
|--------------------------|--------------------------|-------------------------------|-------------------------------|----------------|---------------------------------|
|                          |                          | Unadjusted                    | Adjusted                      | Unadjusted     | Adjusted                        |
|                          |                          | HPV+                          | HPV−                          | HPV+           | HPV−                           |
|                          |                          | HPV status unknown            | HPV status unknown            | p              | HPV+ vs. HPV−                   |
|                          |                          | HPV status unknown            | HPV status unknown            | p              | HPV+ vs. HPV−                   |
|                          |                          | p value for pairwise comparisons | p value for pairwise comparisons | p value for pairwise comparisons | p value for pairwise comparisons |
| Emotional<sup>a</sup>    |                          | 20–80                         | 20–80                         |                |                                |
| Anxiety (STAI-6)         |                          | 45.74 (1.18)                  | 40.52 (0.53)                  | 41.17 (1.33)   | 41.67 (4.05)                   | 37.08 (3.88) | 37.79 (4.04) | 0.003 | 0.002 | 0.098 | 1.00 |
| General distress (GHQ-12)|                          | 3.36 (0.30)                   | 2.75 (0.14)                   | 2.91 (0.34)    | 3.35 (1.02)                   | 2.95 (0.98) | 3.10 (1.02) | 0.475 | 0.691 | 1.00 | 1.00 |
| Emotional distress (CSQ) |                          | 12.29 (0.28)                  | 8.00 (0.13)                   | 8.35 (0.31)    | 11.88 (0.94)                  | 7.71 (0.90) | 8.01 (0.94) | <0.001 | <0.001 | <0.001 | 1.00 |
| Psychosexual distress (PEAPS-Q<sup>b</sup>) | 1–6 | 1.99 (0.90) | 2.30 (0.32) |

| Knowledge<sup>c</sup> |                          | 0–16                          | 0–16                          |                |                                |
| HPV Knowledge           |                          | 13.36 (0.27)                  | 11.50 (0.12)                  | 10.69 (0.30)   | 11.96 (0.94)                  | 10.36 (0.90) | 9.66 (0.93) | <0.001 | <0.001 | <0.001 | 0.091 |
| HPV Testing knowledge   |                          | 0–5                           | 0–5                           |                |                                |
|                          |                          | 4.03 (0.12)                   | 3.27 (0.06)                   | 2.96 (0.14)    | 3.94 (0.40)                   | 3.28 (0.39) | 3.00 (0.40) | <0.001 | <0.001 | <0.001 | 0.195 |

---

<sup>a</sup>Adjusted for age, education, country of birth, relationship status and cervical screening pre-December 2017.

<sup>b</sup>Only women in the HPV+ group were asked to complete the PEAPS-Q items.

<sup>c</sup>Adjusted for age, education, country of birth, relationship status, cervical screening pre-December 2017 and HPV vaccine receipt.
### TABLE 3 Odds of reporting psychosocial outcomes by HPV result group (compared to HPV− group)

|                | Proportion reporting each psychosocial outcome | Unadjusted odds of reporting psychosocial outcome | Adjusted odds of reporting psychosocial outcome |
|----------------|----------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                | HPV− OR (95% CI)                              | HPV+ OR (95% CI)                                | HPV status unknown OR (95% CI)                  |
| Perceived risk in lifetime  
(a) | 140 (20.9)                                   | 78 (56.9)                                       | 33 (30.6)                                       | 5.01 (3.40–7.36)*** | 1.67 (1.06–2.61)* | 4.69 (3.14–6.99)*** | 1.63 (1.03–2.57)* |
| Perceived risk compared to average women  
(b) | 95 (14.1)                                    | 76 (55.4)                                       | 22 (20.4)                                       | 7.54 (5.05–11.26)*** | 1.55 (0.92–2.61) | 7.31 (4.82–11.11)*** | 1.53 (0.91–2.58) |
| Cancer worry  
(c) | 40 (5.9)                                      | 38 (27.8)                                       | 6 (5.6)                                         | 6.05 (3.70–9.89)*** | 0.93 (0.38–2.24) | 5.81 (3.47–9.73)*** | 0.89 (0.36–2.17) |
| Concern about test result  
(d) | 503 (75.1)                                    | 22 (16.0)                                       | 45 (41.7)                                       | 0.13 (0.09–0.19)*** | 0.27 (0.17–0.43)*** | 0.13 (0.09–0.20)*** | 0.26 (0.17–0.42)*** |
| Reassurance about test result  
(e) | 48.4%                                        | 42.4%                                           | 57.6%                                           | 0.67 (0.50–0.80)*** | 0.49 (0.35–0.67)*** | 0.62 (0.45–0.85)*** | 0.48 (0.33–0.68)*** |

Note: Adjusted for age, education, country of birth, relationship status and cervical screening pre-December 2017.

- Women responding ‘medium chance’ or ‘high chance’ to the item ‘What are your chances of developing cervical cancer in your lifetime?’.
- Women responding ‘slightly above average’ or ‘much above average’ to the item ‘What is your lifetime chance of getting cervical cancer compared to a woman of your age and race without any known risk factors?’.
- Women responding ‘quite worried’ or ‘very worried’ to the item ‘How worried are you of getting cervical cancer in your lifetime?’.
- Women responding ‘moderately concerned’ or ‘very concerned’ to the item ‘How concerned do you feel about your recent cervical screening result?’.
- Women responding ‘moderately reassured’ or ‘very reassured’ to the item ‘How reassured do you feel about your recent cervical screening result?’.

*p < 0.05, **p < 0.01, ***p < 0.001.

#### DISCUSSION

This study found higher levels of anxiety and emotional distress in women testing HPV+ compared with those testing HPV−, in the context of the Australian cervical screening program in a highly educated sample. Individuals who reported testing HPV+ had significantly greater knowledge of HPV and HPV testing than participants who reported testing HPV−, who were less educated. Those who reported testing HPV+ had significantly greater knowledge of HPV and HPV testing than those who reported testing HPV−, who were less educated. The significant differences in knowledge of HPV were highest in the HPV+ and HPV unknown groups (knowledge of HPV: F[2, 883] = 18.68, p < 0.001; knowledge of HPV testing: F[2, 883] = 62.14, p < 0.001; knowledge of HPV: F[2, 883] = 62.14, p < 0.001).

In contrast, the knowledge of HPV testing differed across the three HPV result groups (knowledge of HPV: F[2, 883] = 18.68, p < 0.001; knowledge of HPV testing: F[2, 883] = 62.14, p < 0.001).

Knowledge of HPV and HPV testing differed significantly across the three HPV result groups (knowledge of HPV: F[2, 883] = 18.68, p < 0.001; knowledge of HPV testing: F[2, 883] = 62.14, p < 0.001). Post-hoc tests revealed that participants who reported testing HPV+ had significantly greater knowledge of HPV and HPV testing than participants who reported testing HPV− or HPV unknown (all p < 0.001). There were no significant differences in knowledge of HPV between the HPV+ and HPV unknown groups (knowledge of HPV: F[1, 883] = 0.93, p = 0.33).
have an adverse psychological impact on individuals who report testing HPV+ in primary screening beyond 6 month. This is contrary to previous findings, as one third of respondents in this sample had their last cervical screening test over 18 months prior to completing the survey. Average anxiety scores among participants who reported testing HPV+ in this sample were still raised well above scores of the general population, consistent with other studies of individuals who reported testing HPV+. Qualitative research has found that individuals testing HPV+ report feeling low levels of control, confusion about the meaning of results, concern about developing cancer, and shame regarding the mode of acquiring HPV, all contributing to emotional distress regarding HPV+ results. It is unclear what information individuals receive with their test results about HPV and the implications of their results, and this requires further investigation.

The lower levels of anxiety demonstrated in this sample among participants who reported testing HPV+ compared to a previous Australian sample may be driven by improved knowledge about HPV and a longer average interval since the screening test. In comparison to our previous study, a larger proportion of this sample responded correctly to knowledge questions about HPV and HPV testing. However, sizeable gaps in knowledge were still apparent, with less than half of the respondents aware that most sexually active individuals have HPV, and only 29% aware that HPV often doesn’t require treatment, knowledge known to ameliorate stigma and self-blame associated with testing HPV+. These findings support earlier research supporting the need for practitioners to routinely provide tailored information resources about HPV to patients, including possible test results, what they mean, and for those who test HPV+, ongoing management options. Future research is needed to investigate the association between length of time since screening and psychological impact, similar to studies conducted in England.

In contrast to anxiety measures, distress specific to cervical screening was higher relative to previous studies. These results might reflect recruitment methodology; Instagram and Facebook users were younger women and may have a higher propensity to use the Internet to search for information about their results. The use of Internet searches for health information has been associated with increased health-related distress.

Finally, 12% of participants did not know their HPV result from their latest cervical screening test. This proportion is unchanged from a previous Australian sample in 2017 and remains concerning. It is possible that these participants had forgotten, as some research suggests that results with less emotion attached, that is negative results, become less memorable. Another possibility is that these participants were not informed of their result or did not understand what they were told. All practices should ensure they have routine procedures in place to inform patients of their results even if they are normal, as anxiety and emotional distress levels in this group were high. Beyond test results, only half of respondents reported attending regularly for cervical screens. This is a lower proportion relative to the 2017 data, which may be attributable to their younger age, although it is in line with government data that suggests around 52% of Australian women attended regularly for cervical screening when the two yearly interval was in place.

4.1 Study limitations

Our sample is self-selected and differs significantly from the Australian population, with an increased proportion of participants reporting testing HPV+ in comparison to the general public (15% vs. 6.5% in all Australian women), participants being more educated (90% Bachelor level vs. 37.1% of all Australian women) and less ethnically diverse (85% Australian born vs. 70% 2016 census). Nonetheless, our results support prior studies finding that testing HPV+ may be associated with short term psychosocial distress. This survey was conducted as the COVID-19 pandemic began, when general anxiety may have been somewhat elevated across all participants. However, data collection was stopped early to help minimise the impact of the pandemic on the results. Due to this, we did not reach the required sample size so all results should be interpreted with caution. Also, the differences in anxiety levels between participants who reported testing HPV+ and participants who reported testing HPV− were broadly consistent with the literature. We did not obtain medical data for the participants in this sample and therefore cannot verify their self-reported cervical screening test result; however, previous studies have shown that respondents are often accurate in reporting their cancer screening history.

4.2 Clinical implications

This study highlights elevated anxiety and emotional distress in individuals testing HPV+, two years following the renewal of the NCSP. Understanding what information individuals receive both prior to and following their cervical screening test is pertinent to ensure information needs are addressed in ways which may also minimise psychosocial impact.

4.3 Conclusions

Individuals who reported testing HPV+ 2 years following implementation of the renewed NCSP in Australia still reported significantly higher anxiety, concern, and specific distress about test results than those individuals who reported testing HPV−. Future research evaluating the provision of information about HPV, test results and next steps on anxiety and distress, would be valuable.

Acknowledgements

We thank all study participants. This work was supported by a University of Sydney fellowship awarded to Rachael H. Dodd (#197589).
CONFLICT OF INTEREST
Julia M. L. Brotherton’s employer VCS Foundation has received donated human papillomavirus (HPV) tests kits and equipment for unrestricted research purposes from HPV test manufacturers including Roche, Cepheid, Seegene and Becton Dickinson.

ETHICS APPROVAL
This study was approved by The University of Sydney Human Ethics Committee (2018/836).

AUTHOR CONTRIBUTIONS
Rachael H. Dodd and Kirsten J. McCaffery conceived, designed and developed the methods for the study. Rachael H. Dodd coordinated the running of the study. Kirsty F. Bennett and Rachael H. Dodd contributed to the analysis. Verity Chadwick and Rachael H. Dodd drafted the manuscript. Julia M. L. Brotherton contributed to the content and critical analysis. All authors contributed to the interpretation of the analysis and critically revised the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author, Rachael H. Dodd, upon reasonable request.

REFERENCES
1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203.
2. Australian Institute of Health and Welfare (AIHW), National Cervical Screening Program Monitoring Report 2020. AIHW. 2020.
3. Hall MT, Simms KT, Lew J-B, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–e27.
4. Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96–e107.
5. McBride E, Tatar O, Rosberger Z, et al. Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysis. Health Psychol Rev. 2020;15(3):1–35.
6. Dodd RH, Mac O, Brotherton JM, Cvejic E, McCaffery KJ. Levels of anxiety and distress following receipt of positive screening tests in Australia’s HPV-based cervical screening programme: a cross-sectional survey. Sex Transm Infect. 2020;96(3):166–172.
7. Bickford J, Barton S, Mandalia S. Chronic genital herpes and disclosure… The influence of stigma. Int J STD AIDS. 2007;18(9):589–592.
8. Ogilvie GS, Smith LW, van Niekerk D, et al. Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. BMC Publ Health. 2016;16(1):1–8.
9. Jayasinghe Y, Rangiah C, Gorelik A, et al. Primary HPV DNA based cervical cancer screening at 25 years: views of young Australian women aged 16–28 years. J Clin Virol. 2016;76(Suppl 1):S74–e80.
10. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger state–trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31(3):301–306.
11. Wardle J, Pernet A, Stephens D. Psychological consequences of positive results in cervical cancer screening. Psychol Health. 1995;10(3):185–194.
12. Goldberg D. A User’s Guide to the General Health Questionnaire. Windsor; 1988.
13. Bennetts A, Irwig L, Oldenburg B, et al. PEAPS-Q: a questionnaire to measure the psychosocial effects of having an abnormal pap smear. J Clin Epidemiol. 1995;48(10):1235–1243.
14. McBride E, Marlow L, Forster AS, et al. Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme. BMJ open. 2016;6(12):e014356.
15. Hersch J, Barratt A, Jansen J, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 2015;385(9978):1642–1652.
16. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study, Bmj. 2004;328(7451):1293.
17. Ziarnowski KL, Brewer NT, Weber B. Present choices, future outcomes: anticipated regret and HPV vaccination. Prev Med. 2009;48(5):411–414.
18. Waller J, Ostini R, Marlow LA, McCaffery K, Zimet G. Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. Prev Med. 2013;56(1):35–40.
19. Lipkus IM, Klein WM, Skinner CS, Rimer BK. Breast cancer risk perceptions and breast cancer worry: what predicts what? J Risk Res. 2005;8(5):439–452.
20. Kwan TT, Cheung AN, Lo SS, et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstetricia Gynecol Scand. 2011;90(5):445–451.
21. Marteau TM, Kidd J, Cuddeford L, Walker P. Reducing anxiety in women referred for colposcopy using an information booklet. Br J Health Psychol. 1996;1(2):181–189.
22. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer. 2005;92(6):990–994.
23. Conaglen H, Hughes R, Conaglen J, Morgan J. A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus. Int J STD AIDS. 2001;12(10):651–658.
24. Daley EM, Perrin KM, McDermott RJ, et al. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. J health Psychol. 2010;15(2):279–290.
25. Dodd RH, Mac OA, McCaffery KJ. Women’s experiences of the renewed National Cervical Screening Program in Australia 12
months following implementation: a qualitative study. BMJ open. 2020;10(7):e039041.

26. Marlow LAV, McBride E, Ridout D, Forster AS, Kitchener H, Waller J. Patterns of Anxiety and Distress over 12 Months Following Participation in HPV Primary Screening. Sexually Transmitted Infections; 2021. sextrans-2020-054780.

27. Bennett KF, Waller J, McBride E, et al. Psychosexual distress following routine primary human papillomavirus testing: a longitudinal evaluation within the English Cervical Screening Programme. BJOG Int J Obstetrics Gynaecol. 2021;128(4):745-754.

28. Te Poel F, Baumgartner SE, Hartmann T, Tanis M. The curious case of cyberchondria: a longitudinal study on the reciprocal relationship between health anxiety and online health information seeking. J Anxiety Disord. 2016;43:32-40.

29. Kensinger EA. Remembering the details: effects of emotion. Emot Rev. 2009;1(2):99-113.

30. Australian Bureau of Statistics. QuickStats Canberra; 2016. September 28, 2021. https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/2016%20QuickStats

31. Anderson J, Bourne D, Peterson K, Mackey K. Evidence Brief: Accuracy of Self-Report for Cervical and Breast Cancer Screening. Department of Veterans Affairs (US); 2019.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Chadwick V, Bennett KF, McCaffery KJ, Brotherton JML, Dodd RH. Psychosocial impact of testing human papillomavirus positive in Australia’s human papillomavirus-based cervical screening program: a cross-sectional survey. Psychooncology. 2022;31(7):1110-1119. https://doi.org/10.1002/pon.5897